Identification of cancer stem cells in Ewing's sarcoma.

Détails

ID Serval
serval:BIB_62863684C0F1
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Identification of cancer stem cells in Ewing's sarcoma.
Périodique
Cancer research
Auteur⸱e⸱s
Suvà M.L., Riggi N., Stehle J.C., Baumer K., Tercier S., Joseph J.M., Suvà D., Clément V., Provero P., Cironi L., Osterheld M.C., Guillou L., Stamenkovic I.
ISSN
1538-7445 (Electronic)
ISSN-L
0008-5472
Statut éditorial
Publié
Date de publication
01/03/2009
Peer-reviewed
Oui
Volume
69
Numéro
5
Pages
1776-1781
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Résumé
Cancer stem cells that display tumor-initiating properties have recently been identified in several distinct types of malignancies, holding promise for more effective therapeutic strategies. However, evidence of such cells in sarcomas, which include some of the most aggressive and therapy-resistant tumors, has not been shown to date. Here, we identify and characterize cancer stem cells in Ewing's sarcoma family tumors (ESFT), a highly aggressive pediatric malignancy believed to be of mesenchymal stem cell (MSC) origin. Using magnetic bead cell separation of primary ESFT, we have isolated a subpopulation of CD133+ tumor cells that display the capacity to initiate and sustain tumor growth through serial transplantation in nonobese diabetic/severe combined immunodeficiency mice, re-establishing at each in vivo passage the parental tumor phenotype and hierarchical cell organization. Consistent with the plasticity of MSCs, in vitro differentiation assays showed that the CD133+ cell population retained the ability to differentiate along adipogenic, osteogenic, and chondrogenic lineages. Quantitative real-time PCR analysis of genes implicated in stem cell maintenance revealed that CD133+ ESFT cells express significantly higher levels of OCT4 and NANOG than their CD133- counterparts. Taken together, our observations provide the first identification of ESFT cancer stem cells and demonstration of their MSC properties, a critical step towards a better biological understanding and rational therapeutic targeting of these tumors.
Mots-clé
AC133 Antigen, Animals, Antigens, CD/analysis, Bone Neoplasms/pathology, Cell Line, Tumor, Glycoproteins/analysis, Humans, Immunomagnetic Separation/methods, Mice, Neoplastic Stem Cells/pathology, Peptides/analysis, Sarcoma, Ewing/pathology
Pubmed
Web of science
Création de la notice
20/05/2009 18:28
Dernière modification de la notice
20/08/2019 14:19
Données d'usage